Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: Value of laboratory tests as predictors of clinical performance

Vaccine

Volumn 15, Issue 1, 1997, Pages 51-60

  Miller, E ^a   Ashworth, L A E ^a   Redhead, K ^b   Thornton, C ^a   Waight, P A ^a   Coleman, T ^c  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c HEREFORD COUNTY HOSPITAL   (United Kingdom)

Author keywords

antibody persistence to acellular and whole cell pertussis vaccines; laboratory performance of acellular and whole cell pertussis vaccines; schedule for acellular and whole cell pertussis vaccines

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TOXOID; PERTUSSIS VACCINE; TETANUS TOXOID;

ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; LABORATORY TEST; MAJOR CLINICAL STUDY; PERTUSSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ANTIBODIES, BACTERIAL; CHILD, PRESCHOOL; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFANT; PERTUSSIS VACCINE;

EID: 0031025978     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(96)00112-0     Document Type: Article

References (27)

1. 1 Robinson, A. and Ashworth, L.A.E. Acellular and defined-component vaccines against pertussis. In: Pathogenesis and Immunity in Pertussis (Eds Wardlaw, A.C. and Parton, R.). Wiley and Sons, Chichester, 1988, pp. 399-417
2. 2 Edwards, K.M., Bradley, R.B., Decker, M.D. et al. Evaluation of a new highly purified pertussis vaccine in infants and children. J. Infect. Dis. 1989, 160, 832-836
3. 3 Cherry, J.D., Mortimer, E.A., Hackell, J.G., Scott, J.V. and the Multicenter APDT Vaccine Study Groups. Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. International Symposium on Pertussis: Evaluation and Research on Acellular Pertussis Vaccines. Dev. Biol. Standard 1991, 73, 51-58
4. 4 Pichichero, M.E., Francis, A.B., Blatter, M.M. et al. Acellular pertussis vaccination of 2-month-old infants in the United States. Pediatrics 1992, 89, 882-887
5. 5 Vanura, H., Just, M., Ambrosch, F. ef al. Study of pertussis vaccines in infants: comparison of response to acellular Pertussis vaccines containing 25 μg of FHA and either 25 or 8 μg of PT with response to whole-cell pertussis DTP vaccine. Vaccine 1994, 12, 210-214
6. 6 Gustafsson, L., Hallander, H.O., Olin, P., Reizenstein, E. and Storsaeter, J.A. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 1996, 334, 349-355
7. 7 Greco, D., Salamaso, S., Mastrantonio, P. et al. Clinical efficacy, immunogenicity and safety of two acellular and one whole-cell pertusiss vaccines: results from the Italian Trial. N. Engl. J. Med. 1996, 334, 341-348
8. 8 Miller, E., Miller, D.L., Ashworth, L.A.E., Waight, P.A. and Harbert, K.A. Preliminary comparison of antibody responses and symptoms following primary immunisation with British whole cell and three acellular DTP vaccines. Proceedings of Sixth International Symposium on Pertussis (Ed. Manclark, C.R.). Department of Health and Human Services, US. Public Health Service, Bethesda, USA, 1990, pp. 303-309
9. 9 Miller, E., Ashworth, L.A.E., Robinson, A., Waight, P.A. and Irons, L.I. Double blind Phase 2 trial in three month old infants of whole cell pertussis vaccine and an acellular vaccine containing agglutinogens. Lancet 1991, 337, 70-73
10. 10 Gillenius, P., Jäätmaa, E., Askelöf, P., Granström, M. and Tiru, M. The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells. J. Biol. Standard 1985, 13, 61-66
11. 11 Redhead, K. and Seagroatt, V. The effects of purified components of Bordetella pertussis in the weight gain test for the toxicity testing of pertussis vaccines. J. Biol. Standard 1986, 14, 57-65
12. 12 Hewlett, E.L., Roberts, C.O., Wolff, J. and Manclark, C.R. Biphasic effect of pertussis vaccine on serum insulin in mice. Infect. Immun. 1983, 41, 137-144
13. 13 Ishida, S., Kurokawa, M. and Asakawa, S. A new biological assay method for histamine-sensitizing factor using survival time as a response. Jap. J. Med. Sci. Biol. 1976, 29, 139-150
14. 14 Ray, A., Redhead, K., Selkirk, S. and Poole, S. Variability in LPS composition, antigenicity and reactogenicity of phase variants of Bordetella pertussis. FEMS Microbiol. Lett. 1991, 79, 211-218
15. 15 British Pharmacopoeia, Vol II. Test for pyrogens, Appendix XIV, A172-A173. HMSO, London, 1993
16. 16 W.H.O. Expert Committee on Biological Standardization. Technical Report Series, No. 800. W.H.O., Geneva, 1990
17. 17 Melville-Smith, M.E., Seagroatt, V.A. and Watkins, J.T. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J. Biol. Standard 1983, 11, 137-144
18. 18 Zhang, J.M., Cowell, J.L., Steven, A.C. and Manclark, C.R. Purification of serotype 2 fimbriae of Bordetella pertussis and their identification as a mouse protective antigen. Dev. Biol. Standard 1985, 61, 173-185
19. 19 Ramsay, M.E.B., Rao, M., Begg, N.T., Redhead, K. and Attwell, A.M. Antibody response to accelerated immunisation with diphtheria, tetanus, pertussis vaccine. Lancet 1993, 342, 203-206
20. 20 Redhead, K., Watkins, J., Barnard, A. and Mills, K.H.G. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect. Immun. 1993, 61, 3190-3198
21. 21 Department of Health, Welsh Office and Scottish Home and Health Department. Immunisation against Infectious Disease. HMSO, London, 1988
22. 22 Baraff, L.J., Manclark, C.R., Cherry, J.D., Christenson, P. and Marcy, S.M. Analysis of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain. Pediatr. Infect. Dis. J. 1989, 8, 502-507
23. 23 Mussett, M.V. and Sheffield, F.A. Collaborative investigation of methods proposed for the potency assay of adsorbed diphtheria and tetanus toxoids in European Pharmacopoeia. J. Biol. Standard 1973, 1, 259-283
24. 24 Redhead, K., Hill, T.A. and Watkins, J.T. Potentiation of the potency of tetanus toxoid by pertussis vaccine. J. Med. Microbiol. 1991, 35, 187-188
25. 25 Edwards, K.M., Meade, B.D., Decker, M.D. et al. Comparison of 13 acellular pertussis vaccines: Overview and serologic response. Paediatrics 1995, 96, 548-557
26. 26 Miller, E., Vurdien, J.E. and White, J.M. The epidemiology of pertussis in England and Wales. Communicable Dis. Rep. Rev. 1992, 2, R152-R154
27. 27 Miller, E., Rush, M., Ashworth, L.A.E. et al. Antibody responses and reactions to the whole cell pertussis component of a combined diptheria/tetanus/pertussis vaccine given at school entry. Vaccine 1995, 13, 1183-1186